ISK-019

PDCD1; CD274

ID Components Size (96 tests)
ISK-019-1 High-bind Plate 1plate
ISK-019-2 Human PD-1 10μg
ISK-019-3 Biotinylated Human PD-L1 20μg
ISK-019-4 Anti-PD-1 Neutralizing Antibody 20μg
ISK-019-5 Streptavidin-HRP 10μg
ISK-019-6 Coating Buffer 12mL
ISK-019-7 10xWashing Buffer 50mL
ISK-019-8 Blocking Buffer 50mL
ISK-019-9 Substrate Solution 24mL
ISK-019-10 Stop Solution 7mL

Immune checkpoint pathway is a focal point of today’s cancer research. PD-1 is one of the best characterized checkpoint proteins. The binding between PD-1 and its ligand PD-L1 suppresses T-cell activation and allows cancer cells to escape from body’s immune surveillance. Therefore, the pharmaceutical inhibition of PD-1 or its ligand has been considered a promising strategy by many oncologists.

96 tests

5-0.02μg/mL

This inhibitor screening ELISA kit is designed to facilitate the identification and characterization of new PD-1 pathway inhibitors. The assay takes advantage of our in house-developed binding of biotinylated human PD-L1 to immobilized human PD-1 in a functional ELISA assay, and employs a simple colorimetric ELISA platform. Briefly, we provide you with a human Biotinylated PD-L1 protein, a human PD-1 protein, an anti-PD-1 neutralizing antibody (as method verified Std.), and Streptavidin-HRP reagent.
Your experiment will include 4 simple steps:
a) Coat the plate with human PD-1.
b) Add your molecule of interest to the tests.
c) Add human PD-L1-Biotin to bind the coated human PD-1.
d) Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.
Finally, the half maximal inhibitory concentration (IC50) of your compound to PD-1: PD-L1 binding will be determined by comparing OD readings among different experimental groups.

The inhibitor screening ELISA kit is designed to facilitate the identification and characterization of new PD-1 pathway inhibitors.

See Certificate of Analysis for details of reconstitution instruction and specific concentration.

The unopened kit is stable for 12 months from the date of manufacture if stored at 2°C to 8°C.

Serial dilutions of Anti-PD-1 Neutralizing antibody (1:1 serial dilution, from 5μg/mL to 0.02μg/mL) was added into PD-1: Biotinylated PD-L1 binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting.